Physician-assessed effectiveness and safety in adolescent and adult atopic dermatitis patients treated with dupilumab: real-world insights one year into the globostad multinational prospective observational study

Silvia M. Ferrucci¹, Piergiacomo Calzavara-Pinton², Iva Karlova³, Hilde Lapeere⁴, Gregor Holzer⁵, Mona Al-Ahmad⁷, Chia-Yu Chu⁸,⁹, Jiangming Wu¹⁰, Marius Ardeleanu¹¹, Kwinten Bosman¹²

¹Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; ²University of Brescia, Brescia, Italy; ³University Hospital Olomouc, Olomouc, Czech Republic; ⁴Ghent University Hospital, Ghent, Belgium; ⁵Medical University of Vienna, Vienna, Austria; ⁶Sozialmedizinisches Zentrum Ost – Donaupital, Vienna, Austria; ⁷Kuwait University, Kuwait; ⁸National Taiwan University Hospital, Taipei, Taiwan; ⁹National Taiwan University College of Medicine, Taipei, Taiwan; ¹⁰Sanofi, Bridgewater, NJ, USA; ¹¹Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA; ¹²Sanofi, Amsterdam, Netherlands

**Introduction:** Dupilumab demonstrated robust efficacy in patients with moderate-to-severe atopic dermatitis (AD) in randomized controlled trials. Long-term effectiveness of dupilumab in real-world AD treatment is one of the main objectives of the ongoing GLOBOSTAD study.

**Objective:** To report dupilumab effectiveness, through physician-assessed AD clinical tools that measure disease severity over time, and a summary of adverse events in patients one year after initiating treatment.

**Methods:** The GLOBOSTAD five-year, multinational, prospective, observational study (NCT03992417) enrolled patients aged ≥12 years with moderate-to-severe AD. Patients received dupilumab based on country-specific prescribing information. Assessments were performed at baseline, 3 months (M; ±1M), 6M (±2M), and 12M (±2M). Data are reported as observed for enrollment/safety (N = 955; data cutoff: March 2023) and follow-up (N = 903) populations.
Results: 758/863/705 patients completed ≥1 follow-up assessment at 3M/6M/12M, respectively. During the study, mean (SD) eczema area and severity index (EASI; >21 = severe; ≤7 = mild/no disease) score rapidly improved from 25.1 (12.8) at baseline to 6.1 (8.0) at 3M, and was sustained until the end of observation period [12M; 4.2 (8.4)]. Similarly, scoring of atopic dermatitis (SCORAD; >50 = severe; <25 = mild/no disease) score improved from 59.3 (16.6) at baseline to 25.3 (16.4) at 3M, further improving to [17.6 (13.0)] at 12M. Adverse events considered related to dupilumab by the investigator were reported in 187 (19.6%) patients. Adverse events leading to permanent dupilumab discontinuation were reported in 23 (2.4%) patients.

Conclusion: In a real-world scenario, clinical AD assessments rapidly improved upon initiating dupilumab treatment, and were sustained through the end of the one-year observation period. Safety data were consistent with previous studies.

Acknowledgments and Funding Sources:

Data first presented at the 2024 American Academy of Dermatology Association (AAD) Meeting; San Diego CA, March 8-12, 2024. Research sponsored by Sanofi and Regeneron Pharmaceuticals Inc. ClinicalTrials.gov Identifier: NCT03992417. Medical writing/editorial assistance was provided by Sumitra Debina Mitra, PhD of Excerpta Medica, and was funded by Sanofi and Regeneron Pharmaceuticals Inc., according to the Good Publication Practice guidelines.

Keywords: Real-world evidence, dupilumab, atopic dermatitis, adults, adolescents.

Disclosures:

Ferrucci SM: AbbVie, Almirall, Amgen, Bayer, Eli Lilly, Galderma, LEO Pharma, Novartis, Sanofi – principal investigator; Novartis – advisory board member; Almirall, Menarini, Novartis – honoraria for lectures and research grants. Calzavara-Pinton P: AbbVie, Almirall, Cantabria Labs, Celgene, Galderma, Janssen,
LEO Pharma, Meda Pharmaceuticals, Sanofi – advisory board member. **Karlova I:** Sanofi, LEO Pharma, Novartis – advisory board member; Sanofi, LEO Pharma, Novartis – speaker; Sanofi, LEO Pharma, Novartis – investigator. **Lapeere H:** AbbVie, Eli Lilly, LEO Pharma, Pfizer, Sanofi – advisory board member. **Holzer G:** AbbVie, Almirall, Galderma, LEO Pharma, Lilly, Sanofi – advisory board member. **Ahmad M:** AstraZeneca, GSK, Novartis, Sanofi – advisory board member and speaker. **Chu C-Y:** AbbVie, Dermira, Eli Lilly, Novartis, Oneness Biotech, Pfizer, Regeneron Pharmaceuticals Inc., Roche, Sanofi – investigator; AbbVie, Eli Lilly, Novartis, Pfizer, Roche, Sanofi – consultant; AbbVie, Eli Lilly, Mylan, Novartis, Pfizer, Roche, Sanofi – speaker; Mylan, Pfizer, Roche, Sanofi – advisory board member. **Wu J, Bosman K:** Sanofi – employees, may hold stock and/or stock options in the company. **Ardeleanu M:** Regeneron Pharmaceuticals Inc. – employee and shareholder.